To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
NCT04985851
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Extensive-Stage Small-Cell Lung Cancer
Interventions
DRUG:
durvalumab + anlotinib
DRUG:
Durvalumab
Sponsor
Shanghai Chest Hospital